Current management of atopic dermatitis and interruption of the atopic march

Journal of Allergy and Clinical Immunology

Volumn 112, Issue SUPPL. 6, 2003, Pages

  Boguniewicz, Mark ^a,e   Eichenfield, Lawrence F ^b   Hultsch, Thomas ^c,d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

^e NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Asthma; Atopic dermatitis; Atopy; Calcineurin inhibitors; Steroids

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; ETANERCEPT; FLUTICASONE PROPIONATE; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MOMETASONE FUROATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PREDNISONE; PROBIOTIC AGENT; RECOMBINANT GAMMA INTERFERON; TACROLIMUS;

ACNE; ADRENAL INSUFFICIENCY; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DERMATITIS; DESENSITIZATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOOD ALLERGY; GRAFT REJECTION; HUMAN; HYDRATION; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LACTOBACILLUS RHAMNOSUS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; PERIORAL DERMATITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN CARE; SKIN DISEASE; SKIN IRRITATION; STRIA; TELANGIECTASIA; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EID: 0347324950     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2003.09.031     Document Type: Article

References (125)

1. Spergel JM, Pallier ASS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112(suppl):S118-S127.
2. Novak N, Bieber T, Leung DYM. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003;112(suppl):S128-S139.
3. Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol 1985;65:102-5.
4. Macheleidt O, Kaiser HW, Sandhoff K. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol 2002;119:166-73.
5. Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Ichikawa Y, Imokawa G. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol 2002;119:433-9.
6. Sator PG, Schmidt JB, Honigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J Am Acad Dermatol 2003;48:352-8.
7. De Paepe K. Hachem JP, Vanpee E, Roseeuw D, Rogiers V. Effect of rice starch as a bath additive on the barrier function of healthy but SLS-damaged skin and skin of atopic patients. Acta Derm Venereol 2002:82:184-6.
8. Loden M. Biophysical properties of dry atopic and normal skin with special reference to effects of skin care products. Acta Derm Venereol Suppl (Stockh) 1995;192:1-48.
9. Tabata N, O'Goshi K, Zhen YX, Kligman AM, Tagami H. Biophysical assessment of persistent effects of moisturizers after their daily applications: evaluation of corneotherapy. Dermatology 2000;200:308-13.
10. Loden M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br J Dermatol 1999;140:264-7.
11. Hanifin JM, Hebert AA, Mays SR. Effects of a low-potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. Curr Ther Res 1998:59:227-33.
12. Kantor I, Milbauer J, Posner M. Efficacy and safety of emollients as adjunctive agents in topical corticosteroid therapy for atopic dermatitis. Today Trier Trend 1993;11:157-66.
13. Lucky AW, Leach AD, Laskarzewski P, Wenck H. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol 1997;14:321-4.
14. Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002;47:198-208.
15. Nassif A, Chan SC, Storrs FJ, Hanifin JM. Abnormal skin irritancy in atopic dermatitis and in atopy without dermatitis. Arch Dermatol 1994; 130:1402-7.
16. Tabata N, Tagami H, Kligman AM. A twenty-four-hour occlusive exposure to 1% sodium lauryl sulfate induces a unique histopathologic inflammatory response in the xerotic skin of atopic dermatitis patients. Acta Derm Venereol 1998;78:244-7.
17. Breneman DL, Hanifin JM, Berge CA, Keswick BH, Neumann PB. The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis 2000;66:296-300.
18. Diepgen TL, Salzer B, Tepe A. A study of skin irritations caused by textiles under standardized sweating conditions in patients with atopic eczema. Melliand Deutsch/English 1995;12:E268-9.
19. Bendsoe N, Bjornberg A, Asnes H. Itching from wool fibres in atopic dermatitis. Contact Dermatitis 1987;17:21-2.
20. Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 1999;104:S114-22.
21. Fleischer DM, Conover-Walker MK, Christie L, Burks AW, Wood RA. The natural progression of peanut allergy: resolution and the possibility of recurrence. J Allergy Clin Immunol 2003;112:183-9.
22. Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001;107:891-6.
23. Zeiger R, Heller S, Mellon M, et al. Genetic and environmental factors affecting the development of atopy through age 4 in children of atopic parents: a prospective randomized study of food allergen avoidance. Pediatr Allergy Immunol 1992;3:110-27.
24. Zeiger RS, Heller S. The development and prediction of atopy in high-risk children: follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. J Allergy Clin Immunol 1995;95:1179-90.
25. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 1994;30:35-9.
26. Saarinen UM, Kajosaari M. Breastfeeding as prophylaxis against atopic disease: prospective follow-up study until 17 years old. Lancet 1995;346:1065-9.
27. Isolauri E, Tahvanainen A, Peltola T, Arvola T. Breast-feeding of allergic infants. J Pediatr 1999;134:27-32.
28. Schafer T, Heinrich J, Wjst M, Adam H, Ring J, Wichmann HE. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol 1999;104:1280-4.
29. van Reijsen FC, Bruijnzeel-Koomen CA, Kalthoff FS, Maggi E, Romagnani S, Westland JK, et al. Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 1992;90:184-93.
30. Darsow U, Vieluf D, Ring J. Evaluating the relevance of aeroallergen sensitization in atopic eczema with the atopy patch test: a randomized, double-blind multicenter study - Atopy Patch Test Study Group. J Am Acad Dermatol 1999;40:187-93.
31. Shah D, Hales J, Cooper D, Camp R. Recognition of pathogenically relevant house dust mite hypersensitivity in adults with atopic dermatitis: a new approach? J Allergy Clin Immunol 2002;109:1012-8.
32. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996;347:15-8.
33. Ricci G, Patrizi A, Specchia F, Menna L, Bottau P, D'Angelo V, et al. Effect of house dust mite avoidance measures in children with atopic dermatitis. Br J Dermatol 2000:143:379-84.
34. Friedmann PS, Tan BB. Mite elimination: clinical effect on eczema. Allergy 1998;53:97-100.
35. Oosting AJ, de Bruin-Weller MS, Terreehorst I, Tempels-Pavlica Z, Aalberse RC, de Monchy JG, et al. Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the Dutch mite avoidance study. J Allergy Clin Immunol 2002;110:500-6.
36. Gutgesell C, Heise S, Seubert S, Seubert A, Domhof S, Brunner E, et al. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. Br J Dermatol 2001;145:70-4.
37. Holm L, Bengtsson A, van Hage-Hamsten M, Ohman S, Scheynius A. Effectiveness of occlusive bedding in the treatment of atopic dermatitis: a placebo-controlled trial of 12 months' duration. Allergy 2001:56:152-8.
38. Koopman LP, van Strien RT, Kerkhof M, Wijga A, Smit HA, de Jongste JC, et al. Placebo-controlled trial of house dust mite-impermeable mattress covers: effect on symptoms in early childhood. Am J Respir Crit Care Med 2002:166:307-13.
39. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992;22:440-6.
40. Mastrandrea F, Serio G, Minelli M, Minardi A, Scarcia G, Coradduzza G, et al. Specific sublingual immunotherapy in atopic dermatitis: results of a 6-year follow-up of 35 consecutive patients. Allergol Immunopathol (Madr) 2000;28:54-62.
41. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111:87-90.
42. Kopp MV, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;110:728-35.
43. Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003;348:986-93.
44. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076-9.
45. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003;361:1869-71.
46. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003;111:389-95.
47. Barnes PJ. New directions in allergic diseases: mechanism-based anti-inflammatory therapies. J Allergy Clin Immunol 2000;106:5-16.
48. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992;27:29-34.
49. Stalder JF, Fleury M, Sourisse M, Rostin M, Pheline F, Litoux P. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994;131:536-40.
50. Volden G. Successful treatment of therapy-resistant atopic dermatitis with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol Suppl (Stockh) 1992;176:126-8.
51. McLean CJ, Lobo RF, Brazier DJ. Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment. Lancet 1995;345:330.
52. Weston WL, Lane AT, Morelli JG. Color textbook of pediatric dermatology, 2nd ed. St Louis: Mosby; 1996, p. 358.
53. Long CC, Mills CM, Finlay AY. A practical guide to topical therapy in children. Br J Dermatol 1998;138:293-6.
54. Friedlander SF, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002;46:387-93.
55. Wolkerstorfer A, Strobos MA, Glazenburg EJ, Mulder PG, Oranje AP. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol 1998;39:226-31.
56. Lebwohl M. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. Int J Dermatol 1999;38:604-6.
57. Thomas KS, Armstrong S, Avery A, Po AL, O'Neill C, Young S, et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ 2002;324:768.
58. Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate: The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999;140:1114-21.
59. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528-37.
60. Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003;326:1367.
61. Matura M, Goossens A. Contact allergy to corticosteroids. Allergy 2000;55:698-704.
62. Clayton MH, Leung DY, Surs W, Szefler SJ, Altered glucocorticoid receptor binding in atopic dermatitis. J Allergy Clin Immunol 1995;96:421-3.
63. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-6.
64. Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Hypothalamicpituitary- adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000;105:794-9.
65. Lutgemeier MD, Lubach D. Development and regression of dermal corticosteroid atrophy. 4. Concentration dependence of the skin thinning effect of triamcinolone acetonide. Derm Beruf Umwelt 1987;35:55-7.
66. Oikarinen A, Autio P. New aspects of the mechanism of corticosteroid-induced dermal atrophy. Clin Exp Dermatol 1991;16:416-9.
67. Hardie RA, Waring AJ, Barnetson RS. Atrophic skin striae following the use of clobetasol propionate ointment. Practitioner 1977;219:376-8.
68. Berth-Jones J, Graham-Brown RA, Marks R, Camp RD, English JS, Freeman K, et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997;136:76-81.
69. De Rie MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991;71:452-4.
70. Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 1988;47:127-33.
71. Jonas S, Bechstein WO, Tullius SG, Steinmuller T, Gamm T, Neuhaus P. Indications for tacrolimus anti-rejection therapy in liver allograft recipients. Transpl Int 1996;9(suppl 1):S164-70.
72. Bekersky I, Fitzsimmons W, Tanase A, Maher RM, Hodosh E, Lawrence I. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001;44:S17-27.
73. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children: Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998;102:637-44.
74. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44:547-57.
75. Protopic (package insert). Deerfield (Ill): Fujisawa Healthcare Inc.
76. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997;137:568-76.
77. Elidel (package insert). East Hanover (NJ): Novartis Pharmaceuticals Corporation.
78. 77a. Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003;111:1153-68.
79. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989:143:718-26.
80. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981): preclinical pharmacologie profile and skin selectivity. Semin Cutan Med Surg 2001;20:233-41.
81. Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998;290:501-7.
82. Panhans-Gross A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001;107:345-52.
83. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002;46:228-41.
84. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, et al. A short-term trial of tacrolimus ointment for atopic dermatitis: European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337:816-21.
85. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children: Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998;102:637-44.
86. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part 1, efficacy. J Am Acad Dermatol 2001;44:S28-38.
87. Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part 11, safety. J Am Acad Dermatol 2001;44:S39-46.
88. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44:S47-57.
89. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis: The European Tacrolimus Ointment Study Group. Arch Dermatol 2000;136:999-1006.
90. Kawashima M. FK506 Ointment Study Group: long-term treatment with FK506 (tacrolimus) ointment in patients with atopic dermatitis -analysis at the time of 2 year observation. Rinsho Iyako 2001; 17:705-26.
91. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001;44:S58-64.
92. Remitz A, Kyllonen H, Granlund H, Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001;107:196-7.
93. Fleischer AB Jr, Ling M, Eichenfield L, Satoi Y, Jaracz E, Rico MJ, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002;47:562-70.
94. Wahn U, Panser D, Gottlieb AB, Kaufmann R, Eichenfield L, Lagely R, et al. Low blood concentrations of SDZ ASM 981 in infants with extensive atopic dermatitis treated with cream 1%. Presented at 59th Annual Meeting of the American Academy of Dermatology, Washington, DC, 2001.
95. Thaci D, Kaufmann R, Scott G, Ebelin ME. Consistently low blood levels of pimecrolinius (Elidel, SDZ ASM 981) after occlusive topical treatment of chronic hand dermatitis (abstract). J Eur Acad Dermatol Venereol 2001;15:196.
96. Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002;119:876-87.
97. Scott G, Greig G, Oral SDZ ASM 981: pharmacokinetic profile in humans. Presented at 59th Annual Meeting of the American Academy of Dermatology, Washington, DC, 2001.
98. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504.
99. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2.
100. Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC. et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-84.
101. Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003;142:155-62.
102. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002;205:271-7.
103. Eichenfield LF, Hanifin JM, Beck LA, Lemanske RF Jr, Sampson HA, Weiss ST, et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 2003;111:608-16.
104. Ellis C, Luger T, Abeck D, Allen R, Graham-Brown RA, De Prost Y, et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003;148(suppl 63):3-10.
105. Boguniewicz M, editor. Atopic dermatitis. Immunol Allergy Clinics North Am 2002;22:1-178.
106. Jekler J, Larkö O. UVA solarium versus UVB phototherapy of atopic dermatitis: a paired-comparison study. Br J Dermatol 1991;125:569-72.
107. George SA, Bilsland DJ, Johnson BE, Ferguson J. Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. Br J Dermatol 1993;128:49-56.
108. Grundmann-Kollmann M, Behrens S, Podda M, Peter RU, Kaufmann R, Kerscher M. Phototherapy for atopic eczema with narrow-band UVB. J Am Acad Dermatol 1999;40(pt 1):995-7.
109. Sheehan MP, Atherton DJ, Norris P, Hawk J. Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. Br J Dermatol 1993;129:431-6.
110. Reynolds NJ, Franklin V, Gray JC, Diffey BL, Fair PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomized controlled trial. Lancet 2001;357:2012-6.
111. Tzaneva S, Seeber A, Schwaiger M, Honigsmann H, Tanew A. High-dose versus medium-dose-UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol 2001;45:503-7.
112. Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. Clin Exp Dermatol 2000;25:559-66.
113. Leung DYM, Eichenfield LF, Boguniewicz M. Atopic dermatitis (atopic eczema). In: Freedberg IM, Eisen AZ, Wolff K, et al, editors. Fitzpatrick's dermatology in general medicine (6th ed). New York: McGraw-Hill; 2003. p. 1180-94.
114. Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S, et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol 1996;34:1016-21.
115. Zonneveld IM, De Rie MA, Beljaards RC, Van Der Rhee HJ, Wuite J, Zeegelaar J, et al. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. Br J Dermatol 1996;135(suppl 48):15-20.
116. Hanifin JM, Cooper KD. Guidelines of care for atopic dermatitis. J Am Acad Dermatol 2003. In press.
117. Maloney JM, Morman MR, Stewart DM, Tharp MD, Brown JJ, Rajagopalan R. Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis. Int J Dermatol 1998;37:142-4.
118. Roth HL, Brown EP. Hydrocortisone valerate: double blind comparison with two other topical steroids. Cutis 1978;21:695-8.
119. Turpeinen M. Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol 1988;118:517-22.
120. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986;115:475-84.
121. Beck LA, Leung DY. Allergen sensitization through the skin induces systemic allergic responses. J Allergy Clin Immunol 2000;106 (suppl):S258-63.
122. du Vivier A. Tachyphylaxis to topically applied steroids. Arch Dermatol 1976;112:1245-8.
123. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-13.
124. Singh G, Singh PK. Tachyphylaxis to topical steroid measured by histamine-induced wheal suppression. Int J Dermatol 1986;25:324-6.
125. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002;109:539-46.